Trial NCT04540419
Publication Lioznov D, medRxiv, 2022
Primary outcome on the report: Seroconversion rate, specifically the percentage of individuals with a 4-fold or higher increase in antibody titres to the RBD of the SARS-CoV-2 S protein, 28 days after vaccination.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.